Latest Breaking News On - Enhanced delivery oligonucleotide - Page 5 : comparemela.com

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

CanadaBostonMassachusettsUnited statesLaurence wattsSarah suttonJames mcarthurDrug administrationPepgen incNasdaqHealth canadaGilmartin groupProvides updatePlanned initiationMyotonic dystrophy typeEnhanced delivery oligonucleotide

Stock Market

Stock Market
buffalonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buffalonews.com Daily Mail and Mail on Sunday newspapers.

BostonMassachusettsUnited statesCanadaJames mcarthurSarah suttonLaurence wattsHealth canadaGilmartin groupPepgen incDrug administrationNasdaqEnhanced delivery oligonucleotidePrivate securities litigation reform act

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

BOSTON, May 30, 2023 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe. | May 30, 2023

CanadaBostonMassachusettsUnited statesLaurence wattsJames mcarthurDrug administrationHealth canadaNasdaqGilmartin groupPepgen incInvestigational new drug applicationMyotonic dystrophy typeClinical trialEnhanced delivery oligonucleotidePrivate securities litigation reform act

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data. | May 18, 2023

CanadaBostonMassachusettsUnited statesLaurence wattsJames mcarthurGilmartin groupPepgen incHealth canadaHead of clinical development at pepgenNasdaqClinical trial applicationMichelle mellionClinical developmentDrug safety monitoring boardEnhanced delivery oligonucleotide

PepGen Inc.: PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

- Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 - - Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51

United statesBostonMassachusettsCanadaAmericanSarah suttonLaurence wattsJames mcarthurNasdaqMuscular dystrophy association clinical scientific conferenceGilmartin groupPepgen incAmerican academy of neurologyEnhanced delivery oligonucleotideDystrophy association clinicalAmerican academy